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S U M M A R Y
Objectives: The purpose of this study was to explore the clinical and laboratory characteristics of children
with refractory Mycoplasma pneumoniae pneumonia (RMPP).
Methods: Seventy-six children with RMPP and 26 children with non-refractory M. pneumoniae
pneumonia (NRMPP), conﬁrmed by both serology and ﬂuorescent quantitation PCR in bronchoalveolar
lavage ﬂuid (BALF), were evaluated retrospectively.
Results: Compared to those with NRMPP, children with RMPP were older (66.6  39.0 vs.
48.4  35.4 months, p = 0.038) and had a longer duration of fever (12.7  2.6 vs. 7.5  1.8 days) and
hospital stay (12.1  3.2 vs. 7.4  2.9 days). Children with RMPP presented neutrophil inﬁltration both in
serum and BALF, as well as severe pulmonary lesions with pleural effusion. Children with RMPP had a
signiﬁcantly higher M. pneumoniae DNA load in BALF compared to NRMPP patients, and the M. pneumoniae
load in BALF was signiﬁcantly correlated with neutrophils and inversely correlated with macrophages for
both the NRMPP and RMPP groups. The serum concentrations of tumor necrosis factor alpha (median
114.5 pg/ml, range 49.1–897.9 pg/ml) and interferon gamma (median 376.9 pg/ml, range 221.4–1997.6 pg/
ml) were signiﬁcantly higher in children with RMPP compared to children with NRMPP.
Conclusions: This study indicates that a direct microbe effect and the subsequent induced excessive host
immune response contribute in part to the progression of RMPP.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Mycoplasma pneumoniae is one of the most important patho-
gens causing community-acquired pneumonia in adults and
children.1,2 Cyclical outbreaks of M. pneumoniae infection can be
expected on average every 3–7 years, but at any given time M.
pneumoniae may account for as many as 40% of community-
acquired pneumonia cases and 18% of these patients require
hospitalization.3
M. pneumoniae infection is usually a self-limited disease.
However, previous studies have shown that M. pneumoniae
infection can develop into a severe life-threatening disease in* Corresponding author. Tel.: +86 51267788303; fax: +86 512 67786316.
E-mail addresses: szdxjiwei@163.com (W. Ji), chen_zheng_rong@163.com
(Z. Chen).
http://dx.doi.org/10.1016/j.ijid.2014.07.020
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).rare cases, such as refractory M. pneumoniae pneumonia (RMPP),
acute respiratory distress syndrome, necrotizing pneumonitis, and
fulminant pneumonia.4–7 Severe M. pneumoniae pneumonia
appears to occur in deﬁned age groups, whereas older children
aged 5–15 years are more likely to develop bronchopneumonia
involving one or more lobes.3
Generally speaking, drug resistance in M. pneumoniae can affect
the length and severity of illness in patients with pneumonia. In
recent years, the emergence of macrolide-resistant M. pneumoniae
in epidemic, country-wide, and large community settings has been
reported worldwide.1,8–10 In China, macrolide-resistant M. pneu-
moniae is very common and the prevalence ranges from 83% to
95%.11,12 However, the clinical relevance of resistant strains in
RMPP is still the subject of debate worldwide because of a lack
of conclusive evidence.
Besides macrolide resistance, excessive inﬂammation induced
by the host’s cell-mediated immunity also contributes to theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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pneumoniae. This may be associated with the progression of M.
pneumoniae pneumonia, with inﬁltration of neutrophils and
lymphocytes and excessive cytokines or chemokines.13 Excessive
inﬂammation may play a more important role in RMPP than
macrolide resistance in China because of the high prevalence of
macrolide-resistant M. pneumoniae. Several recent studies have
focused on the effectiveness of treatment with corticosteroids in
children with RMPP; it was found that a macrolide combined with
corticosteroids constituted a better treatment option for children
with RMPP than the use of a macrolide alone.7,14,15 However,
further studies are needed to elucidate the associations between
host cell-mediated immunity and the progression of RMPP.
In this study, the clinical and laboratory characteristics of
children with RMPP were investigated, including the relationship
between concentrations of M. pneumoniae DNA and cytology in
bronchoalveolar lavage ﬂuid (BALF) and cytokines in serum.
2. Materials and methods
2.1. Study design
This retrospective, single-center study was conducted in the
children’s hospital afﬁliated with Soochow University, China, from
October 2012 to September 2013. Children were eligible for
enrollment if they were aged 4 weeks to 14 years, had a preceding
fever, and had clinical (tachypnea, chest retractions, or abnormal
ﬁndings on auscultation) and radiological evidence of community-
acquired pneumonia.
A total of 102 children hospitalized with a ﬁnal diagnosis of M.
pneumoniae pneumonia and with M. pneumoniae infection
conﬁrmed in BALF and serum samples using PCR and ELISA were
enrolled. Among these 102 children, 76 were diagnosed with RMPP
and 26 with non-refractory M. pneumoniae pneumonia (NRMPP).
RMPP was diagnosed in the presence of a prolonged high degree
fever (>38.5 8C) and radiological deterioration after therapy with a
macrolide combined with oral prednisolone (azithromycin 10 mg/
day and prednisolone 1–2 mg/day) for 7 days or more.15 Other
children were deﬁned as having NRMPP. In general, a second X-ray
was performed in all children after 5–7 days of treatment to
evaluate radiological changes; radiological deterioration was
deﬁned as an increased area of inﬁltration or pleural effusion
compared to the ﬁrst radiological ﬁndings. Children were excluded
if they had a proven immunodeﬁciency, immunosuppression,
chronic lung disease, or asthma. This study was conducted with the
approval of the Institutional Human Ethics Committee of Soochow
University.
2.2. Patient evaluation
Upon hospital admission and at patient discharge, pediatricians
completed a questionnaire to collect information on the age and
sex of the patient, the duration of symptoms, the clinical
symptoms, the laboratory ﬁndings, and the effectiveness of
treatment with macrolide (azithromycin 10 mg/kg/day once daily
for 5–7 consecutive days). Chest radiography was performed using
standard equipment and radiographic techniques, and all children
enrolled presented unequivocal focal or segmental consolidation
with or without pleural effusion on chest radiography. Peripheral
blood samples were obtained on admission for the determination
of the complete blood count, C-reactive protein concentrations,
platelets, immunoglobulins, subpopulations of T lymphocytes, and
speciﬁc antibody to M. pneumoniae. For 15 children with NRMPP
and 18 children with RMPP, tumor necrosis factor alpha (TNF-a),
interferon gamma (IFN-g), interleukin (IL)-4, and IL-10 were
detected by ELISA, as described previously.16 All children enrolledwere treated with alveolar irrigation and drainage using a
ﬁberoptic bronchoscope.17
2.3. M. pneumoniae serology
The speciﬁc IgM and IgG antibodies against M. pneumoniae were
detected in 2 ml of acute phase (on admission) and convalescent
phase (on discharge) patient serum using a commercial ELISA kit
(SERION ELISA classic M. pneumoniae IgG/IgM; Institute Virion/
Serion, Wu¨rzburg, Germany), in accordance with the manufac-
turer’s instructions and as described previously.18
2.4. BALF collection
The procedure for BALF collection was performed as described
previously.17 The ﬁrst BALF sample was used for the detection of
M. pneumoniae DNA and nine common viruses. The second and
third samples were collected and centrifuged at 200  g for
10 min at 4 8C. Cells were counted after Giemsa and Wright
staining.
2.5. Detection of nine common viruses
A total 2 ml of the ﬁrst BALF sample was centrifuged at 500  g
for 10 min and resuspended in 2 ml saline. It was then divided
equally into two aliquots for pathogen detection by direct
immunoﬂuorescence assay and PCR, as described previously.19
One of the samples was analyzed for seven common viruses
including respiratory syncytial virus, inﬂuenza virus types A and B,
parainﬂuenza virus types 1–3, and adenovirus by direct immuno-
ﬂuorescence assay. The other sample was analyzed for human
metapneumovirus and human bocavirus using reverse transcrip-
tion PCR and real-time PCR.
2.6. Fluorescent quantitation (FQ) PCR for M. pneumoniae gene
detection
A 16S rRNA gene PCR procedure was used for the detection of M.
pneumoniae. In brief, one of the equally divided samples of BALF
was shaken for 30 s and centrifuged at 15 000  g for 5 min. The
sediment was collected and DNA extracted from a 400-ml sample
in accordance with the manufacturer’s instructions. The DNA was
then ampliﬁed using PCR primers and probes. Primers and probes
were synthesized using the following sequences: M. pneumoniae-F:
50-GCAAGGGTTCGTTATTTG-30; M. pneumoniae-R: 50-
CGCCTGCGCTTGCTTTAC-30 (344 bp); M. pneumoniae-probe: 50-
AGGTAATGGCTAGAGTTTGACTG-30 (141 bp). FQ-PCR was per-
formed using a iQ5TM BIO-iCycler (Bio-Rad, California, USA),
and the cycling conditions were as follows: 2 min at 37 8C; 10 min
at 94 8C, and 40 cycles of 10 s at 94 8C, 30 s at 55 8C, and 40 s at
72 8C. Quantiﬁcation curves were plotted using several concentra-
tions of standard control samples, which were purchased from
Daan Gene Co. Ltd (Guangzhou, China). For each assay, a negative
quality control, a critical quality control, a positive quality control,
and four positive quantity controls (105 copies/ml, 106 copies/ml,
107 copies/ml, and 108 copies/ml) were used.
2.7. Statistical analyses
Numeration data were analyzed using the Chi-square test or
Fisher’s exact test and measurement data were analyzed using the
Student t-test or Mann–Whitney U-test if the data distribution was
non-normal. The Pearson or Spearman correlation test was used to
assess correlations among laboratory parameters. Because of the
impact of age on peripheral neutrophils, a general linear model was
used for this analysis. A two-sided p-value of <0.05 was considered
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Windows, version 17.0 software (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Demographic data and clinical and laboratory characteristics of
NRMPP and RMPP
Of the 102 children with M. pneumoniae pneumonia enrolled in
the study, 56 (54.9%) were males. The mean patient age was
61.9 months, ranging from 2 to 162 months. Acute M. pneumoniae
infection was conﬁrmed by both serology and FQ-PCR in serum
and BALF samples. No child required admission to the intensive
care unit at presentation or during their inpatient stay, and all
children received medication treatment with a macrolide and
prednisolone.
Regarding demographic and clinical characteristics, children
with RMPP were slightly older than children with NRMPP, but no
difference in gender distribution was found between the two
groups (Table 1). Fever was the most important symptom for all of
the children with M. pneumoniae infection. Children with RMPP
had a longer duration of fever and length of hospital stay than
children with NRMPP.
Regarding laboratory examinations, the absolute number and
percentage of peripheral neutrophils and levels of C-reaction
protein, IgG, and IgA in children with RMPP were higher than inTable 1
Demographic data and clinical and laboratory characteristics of non-refractory Myco
pneumonia (RMPP) patientsa
Parameter NRMPP (n = 26) 
Age, months 48.4  35.4 
Male 14 (53.8%) 
Hypoxia (Sat. O2 <94%) 3 (11.5%) 
Oxygen therapy 1 (3.8%) 
Tachypnea 4 (15.4%) 
Retraction, n (%) 1 (3.8%) 
Duration of fever, days 7.5  1.8 
Length of stay, days 7.4  2.9 
Peripheral leukocyte count, 109/l 9.4  4.0 
Neutrophil cells, percentage 48.1  15.7 
Neutrophil cells, 109/l 4.1  2.3 
C-reactive protein, mg/l 4.4 (0.8–12.2) 
Platelet count, 109/l 343  121 
Alanine aminotransferase, IU/l 14.1 (10.5–26.5) 
Lactate dehydrogenase, IU/l 364.7 (294.7–448.7) 
MB isoenzyme of creatine kinase, IU/l 23.2 (16.1–28.7) 
Total IgG, g/l 6.9  2.7 
Total IgA, g/l 0.8  0.7 
Total IgM, g/l 1.5  0.7 
Subpopulation of lymphocytes, %
CD3+ 62.9  11.4 
CD3+CD4+ 33  8.9 
CD3CD8+ 26.2  8.0 
CD3CD19+ 23.4  10.6 
CD3CD(16+56+)+ 11.9  4.8 
CD19+CD23+ 11.6  4.9 
Radiological evaluation
Flaky opacity 18 (69.2%) 
Segmental or lobar opacity 7 (26.9%) 
Opacity with pleural effusion 1 (3.8%) 
Cytology of BALF
Macrophage, % 56.4  31.6 
Neutrophil, % 36.2  30 
Lymphocyte, % 7.2  6.3 
Eosinophil, % 0 (0–0) 
Medication
Macrolide 26 (100%) 
Prednisolone 26 (100%) 
Ig, immunoglobulin; BALF, bronchoalveolar lavage ﬂuid.
a Results are presented as the mean  standard deviation, number (percentage), or m
b General linear model analysis was used.children with NRMPP, although no difference was found in total
peripheral leukocyte count, platelet count, alanine aminotransfer-
ase, lactate dehydrogenase, MB isoenzyme of creatine kinase, or
IgM levels, or in the subpopulations of lymphocytes between the
two groups (Table 1). With regard to chest X-ray investigations,
segmental or lobar opacity was the most common ﬁnding in
children with RMPP. Among all children with RMPP, 17 (22.4%)
were reported with pleural effusion, while ﬂaky opacity was more
frequently reported in children with NRMPP. A comparison of the
cytology in BALF between the two groups of children with M.
pneumoniae pneumonia showed that those with RMPP had a higher
percentage of neutrophils and lymphocytes and lower percentage
of macrophages than children with NRMPP (Table 1).
3.2. Analysis of M. pneumoniae DNA copies in BALF in NRMPP and
RMPP patients
Of note, children with RMPP had a signiﬁcantly higher
concentration of M. pneumoniae DNA in BALF than children with
NRMPP (Figure 1) and 54 children (69.7%) with RMPP presented
more than 1  107 copies/ml in BALF. The concentration of M.
pneumoniae (log10/ml) in BALF was signiﬁcantly positively
correlated with neutrophils and inversely correlated with macro-
phages in both the NRMPP and RMPP groups (Figure 2). No
correlation was found between the concentration of M. pneumo-
niae and lymphocytes or eosinophils.plasma pneumoniae pneumonia (NRMPP) and refractory Mycoplasma pneumoniae
RMPP (n = 76) p-Value
66.6  39.0 0.038
42 (55.3%) 0.9003
12 (15.8%) 0.755
10 (13.1%) 0.281
15 (19.7%) 0.774
8 (10.5%) 0.442
12.7  2.6 0.000
12.1  3.2 0.000
9.4  3.8 0.991
63.1  15.9 0.000b
6.1  3.5 0.02b
11.0 (7.7–18.4) 0.033
342  92 0.96
14.1 (10.3–23.0) 0.9
389.1 (307.5–515.9) 0.32
21.4 (16.4–25.4) 0.261
8.4  2.6 0.016
1.2  0.7 0.03
1.7  0.9 0.25
63.4  9.8 0.852
34.4  9.0 0.664
26.1  2.9 0.934
22.4  10.0 0.66
12.3  7.7 0.811
10.4  5.4 0.327
12 (15.8%) 0.000
47 (61.8%) 0.002
17 (22.4%) 0.0372
31.3  22.2 0.000
59.6  24 0.000
9.5  5.6 0.04
0 (0–0) 0.115
76 (100%) 1
76 (100%) 1
edian (25th–75th percentile).
Figure 1. Children with refractory Mycoplasma pneumoniae pneumonia (RMPP) had
signiﬁcantly higher concentrations of M. pneumoniae DNA in bronchoalveolar
lavage ﬂuid than children with non-refractory Mycoplasma pneumoniae pneumonia
(NRMPP) (6.8  0.1 vs. 5.6  0.3; p < 0.0001). M. pneumoniae DNA load data are
presented as log10.
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NRMPP
As shown in Figure 3, the concentrations of serum TNF-a
(median 114.5 pg/ml, range 49.1–897.9 pg/ml) and IFN-g (median
376.9 pg/ml, range 221.4–1997.6 pg/ml) were signiﬁcantly higher
in children with RMPP compared to children with NRMPP. No
difference was found in IL-4 or IL-10 between the RMPP and
NRMPP groups.
4. Discussion
Recently, severe M. pneumoniae pneumonia and cases of RMPP
have been reported worldwide, drawing the attention of clinical
physicians. However, the mechanism of RMPP is still unclear.Figure 2. The concentration of Mycoplasma pneumoniae (log10/ml) in bronchoalveolar 
correlated with macrophages in both the non-refractory Mycoplasma pneumoniae pneum
(RMPP) group (B, D).Pulmonary injury associated with severe or refractory M.
pneumoniae pneumonia may be due to the host’s immune
response rather than to direct microbial damage.3,13,16,20,21 Most
of the recently published studies have been case reports and
the characteristics of RMPP have not been comprehensively
expounded.
The present study focused on clinical and laboratory ﬁndings in
children with RMPP, including cytology in BALF and immunologi-
cal indicators. Of interest, we found that the concentration of M.
pneumoniae was associated with the cytology in BALF, especially
for neutrophils, and that TNF-a and IFN-g play important roles in
the immunopathogenesis of RMPP. This study indicates that both a
direct microbe effect and the host immune response contribute to
the progression of RMPP.
No distinctive clinical manifestation was found between
children with RMPP and those with NRMPP. However, with
regard to radiological ﬁndings, segmental and lobar opacity and
pleural effusion were more frequently found in children with
RMPP than in children with NRMPP, indicating that to some extent
children with RMPP had a more severe illness. In the present
study, 61.8% (47/76) of the total RMPP cases showed segmental or
lobar opacity, which is similar to the 50% (29/58) reported in a
previous study.7
In the present study, RMPP was also found to occur in older
children (age 66.6  39.0 months), which is consistent with the
ﬁnding of a previous study (age 73.2  22.8 months).22 Children older
than 5 years of age have a relatively more mature immune function
than younger children, and this was found to be coincident with high
levels of total IgG and IgA in the present study. However, the host
immune response represents a ‘double-edged sword’. On the one
hand, an appropriate immune response induces macrophage activa-
tion and the elimination of M. pneumoniae in the lung tissue.23 On the
other hand, an inappropriate immune response to M. pneumoniae
causes excessive inﬂammation, which contributes to the develop-lavage ﬂuid was signiﬁcantly positively correlated with neutrophils and inversely
onia (NRMPP) group (A, C) and the refractory Mycoplasma pneumoniae pneumonia
Figure 3. The concentrations of serum interferon gamma (IFN-g) (A) and tumor necrosis factor alpha (TNF-a) (B) were signiﬁcantly higher in children with refractory
Mycoplasma pneumoniae pneumonia (RMPP) compared to children with non-refractory Mycoplasma pneumoniae pneumonia (NRMPP).
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immunodeﬁcient children.24
The present study also showed that a higher M. pneumoniae
load in BALF was directly correlated with disease severity, as found
for another respiratory pathogen, human bocavirus.25 The low
percentage of macrophages may, to some extent, explain the
higher load of M. pneumoniae in BALF, because clearance of M.
pneumoniae depends on activated macrophages not neutrophils.23
In contrast, neutrophils and lymphocytes generate excessive
inﬂammation in lung tissue. In the present study, neutrophils in
BALF were positively correlated with M. pneumoniae load in both
the NRMPP and RMPP groups. The M. pneumoniae membrane
fraction can induce IL-8 expression and secretion as an activator of
neutrophils in human bronchial epithelial cells in vitro,26 and
patients with M. pneumoniae lung infections have increased IL-8 in
their BALF. The levels of IL-8 correlate with higher bacterial loads27
and pulmonary disease severity of M. pneumoniae pneumonia in
children.28 Taken together, it appears that IL-8 acts as a bridge
between M. pneumoniae and neutrophils. Finally, neutrophils
amplify the inﬂammation and injure the airways through the
release of inﬂammatory cytokines, proteases, and reactive oxygen
and nitrogen intermediates.29,30
Inﬂammatory cytokines such as IFN-g and TNF-a also play a
key role in the immunopathogenesis of M. pneumoniae infec-
tion.31–33 The levels of serum IL-18, which promotes Th1 cytokine
responses such as IFN-g, in patients with severe M. pneumoniae
pneumonia were found to be higher than those in mild cases and
were correlated with the number of affected lobes.20 In the present
study, high levels of IFN-g and TNF-a in serum were also shown in
children with RMPP.
A major limitation of this study is the absence of data on
macrolide resistance in M. pneumoniae. The prevalence of
macrolide-resistant M. pneumoniae is increasing rapidly world-
wide, especially in China, where macrolide resistance in M.
pneumoniae ranges up to 95%.12,34 The macrolide resistance in M.
pneumoniae may have little impact on the results of this study
because of the high prevalence of macrolide-resistant M.
pneumoniae in China. However, in contrast, a recent study showed
that serum IFN-g levels were higher in patients with macrolide-
resistant genotypes than in those infected with no-mutation
strains,35 which indicates that macrolide resistance in
M. pneumoniae could play an important role in the development
of RMPP.
In conclusion, although no distinctive clinical manifestation
was found, laboratory examinations may be useful for the
diagnosis and treatment of RMPP. The M. pneumoniae load is
closely correlated with neutrophils and disease severity. Inﬂam-
matory indicators such as TNF-a and INF-g also contribute to the
progression of RMPP. However, further studies in large, well-
characterized patient populations and in vitro studies are neededto elucidate the mechanism and explore the clinical applications of
these observations.
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